What is the difference between Cetrorelix and Kisspeptin-54?

Cetrorelix: Competitive GnRH receptor antagonist; immediately blocks pituitary GnRH receptors; rapidly suppresses LH/FSH without initial flare effect; used for controlled hormonal suppression Kisspeptin-54: Full-length kisspeptin (54 amino acids); binds KISS1R on GnRH neurons with higher receptor occupancy and longer duration than KP-10; induces more sustained GnRH/LH pulses

Is Cetrorelix FDA approved?

Cetrorelix is FDA approved (FDA status current as of 1999-06-03). This regulatory status is provided for research and educational context only.

Is Kisspeptin-54 FDA approved?

Kisspeptin-54 is investigational and not FDA approved. It is discussed for research and educational purposes only, not as medical guidance.

How is Cetrorelix administered in research settings?

In research settings, Cetrorelix is typically administered via the subcutaneous route. PeptideBase does not provide dosing or administration instructions.

How is Kisspeptin-54 administered in research settings?

In research settings, Kisspeptin-54 is typically administered via the subcutaneous or intravenous routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›Cetrorelix vs Kisspeptin-54

Peptide Comparison

Cetrorelix vs Kisspeptin-54

Both are Reproductive & Hormonal peptides.

Cetrorelix

Cetrotide

Sexual HealthFDA ApprovedPrescription

Half-life: ~62 hours

1 providers listed

Full Cetrorelix profile →

Kisspeptin-54

KP-54

Sexual HealthInvestigationalResearch Only

Half-life: ~29 minutes

12 providers listed

Full Kisspeptin-54 profile →

Bottom line

Cetrorelix is FDA-approved, while Kisspeptin-54 is investigational — the clearest structural difference between them.

Quick Verdict

Cetrorelix

Evidence

Established Clinical

Half-life

~62 hours

Kisspeptin-54

Evidence

Established Clinical

Half-life

~29 minutes

Which One Should You Choose?

Your goal	Better option
Further along in FDA review	Cetrorelix
Less frequent dosing (longer half-life)	Cetrorelix
More provider options (1 vs 12)	Kisspeptin-54

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

Cetrorelix

Kisspeptin-54

Mechanism Family

Reproductive & Hormonal

Half-life

~62 hours

~29 minutes

FDA Status

approved

investigational

Admin Routes

subcutaneous

subcutaneous, intravenous

Availability

Prescription

Research Only

Providers

1 listed

12 listed

FDA Update

Jun 1999

—

Avail. Notes

FDA-approved GnRH antagonist. Brand: Cetrotide (NDA 021036, Jun 1999). Prevents premature LH surges in controlled ovarian stimulation. Prescription only.

No FDA approval. Longer-acting kisspeptin isoform under Phase 1/2 investigation for reproductive disorders in EU and US. No NDA filed. Research peptide only.

Research Evidence

Cetrorelix

Established ClinicalMeta-analysis · 7 key studies · most recent 2026

Kisspeptin-54

Established ClinicalRCT · 8 key studies · most recent 2025

Research Citations

Cetrorelix

Meta-analysis2026 · J Coll Physicians Surg Pak

GnRH Agonists and Antagonists in IVF/ICSI Cycles of PCOS Women: A Network Meta-Analysis.

Meta-analysis2023 · Hum Reprod Update

Optimal GnRH antagonist protocol for ovarian stimulation during ART: systematic review and network meta-analy…

Cohort2026 · Eur J Pharm Sci

Hydrogel and oleogel formulation of the decapeptide cetrorelix acetate for nasal administration.

Cohort2026 · Int J Reprod Biomed

Efficacy and safety of different cetrorelix doses in the luteal phase for preventing ovarian hyperstimulation…

+3 more

Kisspeptin-54

Review2025 · Trends in Endocrinology and Metabolism

Can kisspeptin be a new treatment for sexual dysfunction?

Cohort2025 · Journal of Endocrinological Investigation

Phase-dependent changes in serum kisspeptin and irisin levels across the menstrual cycle in healthy women

RCT2022 · JAMA Netw Open

Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical T…

Cohort2020 · Endocrine

Kisspeptin and LH pulsatility in patients with functional hypothalamic amenorrhea

+4 more

About Cetrorelix

Competitive GnRH receptor antagonist; immediately blocks pituitary GnRH receptors; rapidly suppresses LH/FSH without initial flare effect; used for controlled hormonal suppression

Research Areas

HPG axis suppressionLH/FSH reductioncontrolled ovarian stimulation supporttestosterone management

About Kisspeptin-54

Full-length kisspeptin (54 amino acids); binds KISS1R on GnRH neurons with higher receptor occupancy and longer duration than KP-10; induces more sustained GnRH/LH pulses

Research Areas

sustained LH/FSH stimulationtestosterone supportfertility inductionreproductive function

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Cetrorelix

Absolute Contraindications

Pregnancy — contraindicatedLactation — contraindicated

Source: FDA label

Suggested Monitoring

Under clinical review

Being verified by our medical team before we display monitoring guidance for this peptide.

Kisspeptin-54

Reported (Unverified — Pending Clinical Review)

hormone-sensitive cancerspregnancy (during treatment)

No established clinical contraindications

Find Providers

Where to source these peptides

Providers offering

Cetrorelix

1 listed

Browse directory →

Providers offering

Kisspeptin-54

12 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Reproductive & Hormonal Comparisons

Browse all peptides →

Educational research tools — not medical advice.